Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

By LabMedica International staff writers
Posted on 05 Oct 2026

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. More...

Despite this burden, diagnosis can still take months and sometimes more than a year, delaying access to support, treatment, and research opportunities. To help accelerate diagnosis, researchers are advancing a blood biomarker project for use in National Health Service (NHS) memory services.

According to Oxford Health NHS Foundation Trust, the Oxford and Dementias Platform UK (DPUK)-led project centers on integrating blood-based dementia biomarkers into routine NHS memory services. The biomarker panel is currently being validated through the Blood Biomarker Challenge-funded READ-OUT study. The project will now roll out the biomarkers at 6–10 NHS memory service sites as part of the standard clinical pathway to understand how the approach could be implemented across memory clinics.

The project brings together researchers from the Universities of Oxford and Cambridge, Imperial College London, and DPUK. It is one of nine projects selected for the UK Research and Innovation NHS Fit for the Future Dementia Challenge. The program is backed by up to GBP 80 million through the Department for Business and Trade’s Research & Development Missions Accelerator Programme and aims to accelerate adoption of technologies and approaches that could help people receive faster diagnoses of memory disorders by 2029.

The Dementia Challenge is designed to support projects that demonstrate measurable benefits for both patients and health services, with participating teams required to meet key milestones to advance to future funding stages. Within this framework, the project represents a further step toward translating dementia biomarker research into routine clinical practice and aligns with DPUK’s broader mission to accelerate discoveries for people affected by dementia.

“Blood-based biomarkers have the potential to transform dementia diagnosis within NHS memory services. Building on the evidence generated through the READ-OUT study, this project will help us understand how these tests can be integrated into routine clinical pathways and at which point they would be most effective in supporting timely and accurate diagnoses,” said Professor Vanessa Raymont, Director of DPUK and Director of R&D at Oxford Health NHS Foundation Trust.

“We aim to establish a blueprint for their use across the NHS by 2029, which would be truly transformative for services, as earlier diagnosis can help people living with dementia and their families access support, treatment and information at a crucial point in their journey,” added Professor Raymont.

Related Links
Oxford Health NHS Foundation Trust
Dementias Platform UK


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.